CEBPA and familial pancreatic carcinoma: Yoon et al. successfully developed a novel aptamer-based therapy for pancreatic cancer by upregulating the transcription factor CCAAT/enhancer-binding protein-α (C/EBPα), owing to its binding with pancreatic cancer-specific 2’-fluropyrimidine RNA aptamers P19 and P1, which were selected by SELEX, resulting in tumor-suppressive effects [104].